The company’s net loss was $1.3m, compared to a net loss of $2.41m for the same period in 2009.
Antares Pharma has reported operating loss of $1.23m for the fourth quarter of 2010, compared to $2.48m for the same period in 2009.
For the full year ended 31 December 2010, the company posted total revenue of $12.82m, compared to $8.31m for the same period in 2009.
The company’s net loss was $6.09m, compared to a net loss of $10.29m for the same period in 2009.
The company has said that its operating loss for the full year ended 31 December 2010 was $6.03m, compared to $9.69m for the same period, last year.
Antares Pharma president and CEO Paul Wotton said their strategic plan put in place in 2009 to increase focus on the self-injectable technologies has led to the strong financial and operational results demonstrated in both the fourth quarter and the full year of 2010.
"We believe the solid foundation laid in 2010, including increasing product sales and royalties, continued development of the epinephrine product with Teva, the NDA filing for Anturol, and initiation of clinical testing of Vibex MTX, has left us well-positioned for a strong 2011," Wotton said.